You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

HPV Vaccine – Breaking News

25 Nov, 11 | by shellraine, e-Media Editor

Gardasil to be used in the UK HPV vaccination programme from September 2012

Posted by Anne Szarewski, Editor in Chief, JFPRHC

The Department of Health made the announcement this week, though it was an inevitability, since there was only one vaccine being considered. GSK had made the decision not to participate in the tender process back in September, but the DH perhaps wanted to make sure that this year’s school vaccination schedule was not derailed by parental confusion – by now most girls in this year’s programme will have had their first two vaccinations of Cervarix.

While Gardasil offers protection against genital warts, which Cervarix does not, Cervarix has been shown to give greater protection against cervical cancer, due to its much greater cross protection against non-vaccine HPV types. Indeed, this was acknowledged in the recent paper by Jit et al (BMJ 2011;343:d5775 doi: 10.1136/bmj.d5775).

However, there has been mounting pressure for protection against genital warts, so this outcome will be welcomed by many, especially our colleagues in GUM. However, if discussing the decision with parents who may be worried that their daughter was ‘given the wrong vaccine’ we can reassure them that by having Cervarix, those girls will have had the benefit of greater protection against cancer. It is a shame that one has to choose: I have long suggested that a potential solution would be to vaccinate girls with Cervarix and boys with Gardasil, which would give herd immunity against warts, offer protection to MSM and still allow girls the better cancer protection.

Welcome to the Journal of Family Planning blog

28 Sep, 11 | by shellraine, e-Media Editor

My aim is to bring you news, views and information in the field of contraception and sexual health – some of which you may have seen and some not. I hope that as well as highlighting articles and issues from our journal this will signpost current issues and initiatives from the UK and around the world.

It has been an eventful year in contraception with a number of changes for clinical practice and over the coming weeks I will revisit the most important of these.

A round-up of some recent news items includes:

Mary Robinson calls for more funds for Family Planning.

As world leaders collected at the UN in New York last week Mary Robinson, the first woman president of Ireland (1990-1997), UN High Commissioner for Human Rights from 1997-2002, and chairwoman of the Global Leaders Council for Reproductive Health called for them to make good on their promise of 17 years ago at the UN International Conference on Population and Development in Cairo, when they agreed to make contraceptive services available for women all over the world by 2015.

WHO Medical Eligibility Criteria for Contraceptive Use 4th ed wins first prize in the BMA Book Awards (O&G category).

The WHO MEC are the basis from which the UK MEC were developed and underpin clinical practice in contraception and sexual health. The most recent version of the UKMEC was published 2009:

Medscape Education Clinical Briefs report a pooled analysis of 2 studies which seem to demonstrate that Intrauterine Devices Lower Cervical Cancer Risk. This involved 10 case-control studies done in 8 countries, and 16 studies of HPV prevalence from 16 countries looking at risks for cancer of the cervix and HPV in IUD users.

In Rwanda, Africa’s most densely populated country, men are being encouraged to have vasectomies. The no-scalpel procedure is being offered for free according to a report in the Independent Newspaper on 7th September.

Unapproved emergency birth control medicine in U.S. may be ineffective and unsafe. In July the FDA issued a warning to consumers not to buy a product named Evital as they may have been counterfeit.

I welcome comments from readers and will publish those that I feel will be helpful to others.

Latest from JFPRHC

Latest from JFPRHC